ClinicalTrials.gg
Active, not recruitingNCT02511106ADAURAUpdated Sep 11, 2026Results posted

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

A Phase 3 interventional study of AZD9291 80 mg/40 mg and Placebo AZD9291 80 mg/40 mg in Stage IB-IIIA Non-small Cell Lung Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 238 sites in 25 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
682
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 90
682 · median 51
Started
2015
with 4 others
Phase 3
12 of 90
1 open now
Primary completion
2022-04
later than 2 of 42 live
Registered
16th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 5 that started in 2015, is one of 12 in phase 3, reaches primary completion later than 2 of the 42 other live ones, and was the 16th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

Read the detailed description

This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy. Adjuvant chemotherapy should have consisted of a platinum based doublet given for a maximum of 4 cycles.

03

Conditions studied

  • Stage IB-IIIA Non-small Cell Lung Carcinoma

Keywords

  • Stage IB-IIA-IIIA Non-Small Cell Lung Cancer; EGFRm+; Ex19Del; L858R; AZD9291; Phase III, adjuvant chemotherapy; complete tumour resection; EGFR-TKI
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged at least 18 years.
  2. confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology
  3. MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
  4. Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.
  5. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.
  6. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
  7. Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
  8. World Health Organization Performance Status of 0 to 1.
  9. Female patients should be using adequate measures, should not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following:

    • Pre-operative or post-operative or planned radiation therapy for the current lung cancer
    • Pre-operative () platinum based or other chemotherapy
    • Any prior anticancer therapy
    • Prior treatment with neoadjuvant or adjuvant EGFR-TKI at any time
    • Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug
    • Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4
    • Treatment with an drug within five half-lives of the compound or any of its related material.
  2. Patients who have had only segmentectomies or wedge resections
  3. History of other , except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of treatment.
  4. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
  5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including , and (HIV).
  6. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291.
  7. Any of the following cardiac criteria:

    • Mean resting interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic machine-derived QTc value.
    • Any abnormalities in rhythm, conduction, or morphology of resting ECG.
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
  8. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active ILD.
  9. Inadequate bone marrow reserve or organ function.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
682 participants (actual)

Study arms

  • Experimental
    AZD9291

    AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.

    Drug: AZD9291 80 mg/40 mg · Drug: Open-label AZD9291 80 mg/40 mg

  • Placebo comparator
    Placebo AZD9291

    Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.

    Drug: Placebo AZD9291 80 mg/40 mg

Interventions

  • DrugAZD9291 80 mg/40 mg

    Drug page: Osimertinib

    The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.

  • DrugPlacebo AZD9291 80 mg/40 mg

    The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.

  • DrugOpen-label AZD9291 80 mg/40 mg

    Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.

06

What researchers measure

Primary outcomes

  1. Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).

    Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

    Time frame: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)

Secondary outcomes

  1. Disease Free Survival (DFS) Rate at 2, 3 and 5 Years

    Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.

    Time frame: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.

  2. Overall Survival (OS)

    Defined as the time from the date of randomization until date of death due to any cause.

    Time frame: Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)

  3. Overall Survival Rate at 2, 3 and 5 Years

    Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.

    Time frame: Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.

  4. Patient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey.

    Change from baseline will be calculated for each domain and summary scale at each scheduled post-baseline assessment. The SF-36 includes eight domains: Physical Functioning (PF); Role Limitations-Physical (RP), Vitality (VT), General Health Perceptions (GH), Bodily Pain (BP), Social Function (SF), Role Limitations-Emotional (RE), and Mental Health (MH) and two summary scores: The Physical Component Summary (PCS) and Mental Component Summary (MCS). Final scores for each scale range from 0-100 with higher scores indicating better health.

    Time frame: Measured by SF-36 Questionnaire at baseline, 12 week, 24 week and then every 24 weeks until study complete, disease recurrence or other discontinuation criteria met, up to 3 years.

  5. Plasma Concentrations of AZD9291

    The pharmacokinetics exposure parameters derived from plasma concentrations of AZD9291

    Time frame: Collected at pre-dose, 0.5-1.5hours and 2-4hours post-dose up to 96 weeks (approximately 24 months)

  6. Plasma Concentrations of AZ5104 Metabolites

    The pharmacokinetics exposure parameters derived from plasma concentrations of AZ5104 metabolites

    Time frame: From date of dosing to week 96 (approximately 24 months)

  7. Plasma Concentrations of AZ7550 Metabolites

    The pharmacokinetics exposure parameters derived from plasma concentrations of AZ7550 metabolites

    Time frame: From date of dosing to week 96 (approximately 24 months)

07

Results

Posted Jul 27, 2021
Limitations and caveats
Primary analysis was performed two years early as per IDMC recommendation and the exploratory analysis of final DFS data at the prespecified maturity of approx. 50% was done in 2022. After the final DFS data analysis and until the final OS analysis, only limited data were collected: subsequent anti-cancer treatment, survival status and limited safety data. The AZ7550 metabolite samples were not analyzed after Mar 2019, so the ratio of metabolite to AZD9291 was not available for calculation.

Participant flow

A total of 682 Patients were randomized to treatment at 245 Centers in 25 Countries.

Participant flow — Overall Study
MilestoneAZD9291Placebo
Started339343
Received treatment337343
Completed261234
Not completed78109
Withdrew: Lost to follow-up64
Withdrew: Withdrawal by subject2421
Withdrew: Death4282
Withdrew: Ongoing study at data cut-off32
Withdrew: Without specified reason30

Outcome measures

PrimaryAssess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).

Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

Time frame:
Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)
Reported as:
Median · Months
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).
MonthsAZD9291 80mg TabletPlacebo Tablet
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).65.8 (54.4 to NA)21.9 (16.6 to 27.5)
Statistical analysis
  • AZD9291 80mg Tablet vs Placebo Tablet · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.23 · 95% CI 0.18 to 0.30A hazard ratio \<1 favours AZD9291.
PrimaryAssess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).

Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

Time frame:
Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)
Reported as:
Median · Months
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).
MonthsAZD9291 80mg TabletPlacebo Tablet
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).65.8 (61.7 to NA)28.1 (22.1 to 35.0)
Statistical analysis
  • AZD9291 80mg Tablet vs Placebo Tablet · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.27 · 95% CI 0.21 to 0.34A hazard ratio \<1 favours AZD9291.
SecondaryDisease Free Survival (DFS) Rate at 2, 3 and 5 Years

Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.

Time frame:
Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Reported as:
Number · Percentage of participants
Disease Free Survival (DFS) Rate at 2, 3 and 5 Years
Percentage of participantsAZD9291 80mg TabletPlacebo Tablet
DFS rate at 2 years (%)90.0 (85.2 to 93.3)46.1 (39.6 to 52.4)
DFS rate at 3 years (%)83.5 (77.8 to 87.8)33.8 (27.8 to 40.0)
DFS rate at 5 years (%)53.0 (43.0 to 62.1)24.9 (19.0 to 31.2)
SecondaryDisease Free Survival (DFS) Rate at 2, 3 and 5 Years

Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.

Time frame:
Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Reported as:
Number · Percentage of participants
Disease Free Survival (DFS) Rate at 2, 3 and 5 Years
Percentage of participantsAZD9291 80mg TabletPlacebo Tablet
DFS rate at 2 years (%)90.1 (86.2 to 92.9)54.5 (49.0 to 59.7)
DFS rate at 3 years (%)84.5 (79.9 to 88.1)44.4 (39.0 to 49.7)
DFS rate at 5 years (%)60.9 (53.1 to 67.8)33.6 (28.0 to 39.2)
SecondaryOverall Survival (OS)

Defined as the time from the date of randomization until date of death due to any cause.

Time frame:
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAZD9291 80mg TabletPlacebo Tablet
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • AZD9291 80mg Tablet vs Placebo Tablet · Log Rank · p = 0.0004 · Hazard ratio (hr): 0.4913 · 95.03% CI 0.3307 to 0.7299A hazard ratio \<1 favours AZD9291.
SecondaryOverall Survival (OS)

Defined as the time from the date of randomization until date of death due to any cause.

Time frame:
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAZD9291 80mg TabletPlacebo Tablet
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • AZD9291 80mg Tablet vs Placebo Tablet · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.4912 · 95.03% CI 0.3439 to 0.7017A hazard ratio \<1 favours AZD9291.
SecondaryOverall Survival Rate at 2, 3 and 5 Years

Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.

Time frame:
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Reported as:
Number · Percentage of participants
Overall Survival Rate at 2, 3 and 5 Years
Percentage of participantsAZD9291 80mg TabletPlacebo Tablet
OS rate at 2 years (%)99.5 (96.8 to 99.9)92.6 (88.3 to 95.3)
OS rate at 3 years (%)94.1 (90.1 to 96.5)85.9 (80.6 to 89.8)
OS rate at 5 years (%)85.0 (79.3 to 89.2)72.6 (66.0 to 78.1)
SecondaryOverall Survival Rate at 2, 3 and 5 Years

Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.

Time frame:
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Reported as:
Number · Percentage of participants
Overall Survival Rate at 2, 3 and 5 Years
Percentage of participantsAZD9291 80mg TabletPlacebo Tablet
OS rate at 2 years (%)99.4 (97.5 to 99.8)94.3 (91.2 to 96.3)
OS rate at 3 years (%)95.3 (92.3 to 97.1)88.8 (84.9 to 91.8)
OS rate at 5 years (%)87.6 (83.3 to 90.9)77.7 (72.7 to 81.9)
SecondaryPatient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey.

Change from baseline will be calculated for each domain and summary scale at each scheduled post-baseline assessment. The SF-36 includes eight domains: Physical Functioning (PF); Role Limitations-Physical (RP), Vitality (VT), General Health Perceptions (GH), Bodily Pain (BP), Social Function (SF), Role Limitations-Emotional (RE), and Mental Health (MH) and two summary scores: The Physical Component Summary (PCS) and Mental Component Summary (MCS). Final scores for each scale range from 0-100 with higher scores indicating better health.

Time frame:
Measured by SF-36 Questionnaire at baseline, 12 week, 24 week and then every 24 weeks until study complete, disease recurrence or other discontinuation criteria met, up to 3 years.
Reported as:
Mean · Unit on a scale
Patient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey.
Unit on a scaleAZD9291 80mg TabletPlacebo Tablet
Week 12 - Bodily Pain1.026 ± 9.4481.442 ± 8.854
Week 24 - Bodily Pain1.521 ± 9.1711.462 ± 9.279
Week 48 - Bodily Pain2.032 ± 10.2262.438 ± 10.077
Week 72 - Bodily Pain2.471 ± 9.7872.335 ± 9.566
Week 96 - Bodily Pain2.326 ± 10.8652.921 ± 10.153
Week 120 - Bodily Pain2.906 ± 10.1812.778 ± 11.295
Week 144 - Bodily Pain3.045 ± 11.4103.324 ± 10.258
Week 156 - Bodily Pain2.552 ± 11.9943.116 ± 10.692
Week 12 - General Health Perceptions-0.597 ± 8.3190.343 ± 7.497
Week 24 - General Health Perceptions-0.079 ± 8.9100.763 ± 8.122
Week 48 - General Health Perceptions0.103 ± 8.0291.042 ± 8.416
Week 72 - General Health Perceptions0.275 ± 7.9582.339 ± 8.197
Week 96 - General Health Perceptions-0.119 ± 8.1951.818 ± 7.903
Week 120 - General Health Perceptions-0.368 ± 8.4610.964 ± 8.518
Week 144 - General Health Perceptions0.209 ± 8.6711.342 ± 8.789
Week 156 - General Health Perceptions-0.128 ± 8.9872.166 ± 8.670
Week 12 - Mental Health0.928 ± 8.5381.892 ± 8.497
Week 24 - Mental Health1.249 ± 8.7801.275 ± 9.660
Week 48 - Mental Health2.456 ± 8.9202.234 ± 8.676
Week 72 - Mental Health1.540 ± 9.0292.011 ± 8.954
Week 96 - Mental Health1.352 ± 8.5602.101 ± 8.986
Week 120 - Mental Health0.723 ± 9.7382.307 ± 10.139
Week 144 - Mental Health0.517 ± 9.6091.428 ± 8.914
Week 156 - Mental Health0.386 ± 10.2152.000 ± 9.651
Week 12 - Physical functioning-0.314 ± 6.7620.898 ± 6.646
Week 24 - Physical functioning0.494 ± 6.7830.923 ± 7.014
Week 48 - Physical functioning0.940 ± 7.5951.914 ± 7.899
Week 72 - Physical functioning1.079 ± 6.7252.042 ± 7.283
Week 96 - Physical functioning0.637 ± 8.2202.016 ± 7.048
Week 120 - Physical functioning1.449 ± 7.2072.540 ± 7.424
Week 144 - Physical functioning1.869 ± 6.7671.939 ± 8.238
Week 156 - Physical functioning0.997 ± 7.5372.187 ± 8.293
Week 12 - Role Limitations - Emotional0.381 ± 10.4132.333 ± 11.168
Week 24 - Role Limitations - Emotional0.858 ± 11.3171.678 ± 11.571
Week 48 - Role Limitations - Emotional2.179 ± 11.1312.628 ± 10.952
Week 72 - Role Limitations - Emotional1.410 ± 11.8611.860 ± 11.424
Week 96 - Role Limitations - Emotional1.657 ± 12.4051.899 ± 12.379
Week 120 - Role Limitations - Emotional1.765 ± 11.9662.360 ± 12.663
Week 144 - Role Limitations - Emotional1.654 ± 12.0812.532 ± 13.113
Week 156 - Role Limitations - Emotional0.519 ± 12.3512.201 ± 13.022
Week 12 - Role Limitations - Physical1.056 ± 9.2632.915 ± 8.977
Week 24 - Role Limitations - Physical1.727 ± 10.2654.063 ± 9.295
Week 48 - Role Limitations - Physical3.437 ± 10.5925.332 ± 9.663
Week 72 - Role Limitations - Physical3.581 ± 11.0375.424 ± 9.670
Week 96 - Role Limitations - Physical3.240 ± 10.8075.321 ± 9.997
Week 120 - Role Limitations - Physical4.717 ± 11.2385.348 ± 11.395
Week 144 - Role Limitations - Physical3.525 ± 10.8605.444 ± 10.547
Week 156 - Role Limitations - Physical3.151 ± 11.3785.572 ± 10.954
Week 12 - Social Function1.391 ± 9.6153.164 ± 9.171
Week 24 - Social Function2.634 ± 9.5263.433 ± 10.348
Week 48 - Social Function3.731 ± 9.9194.170 ± 10.156
Week 72 - Social Function3.025 ± 10.0944.802 ± 10.351
Week 96 - Social Function3.651 ± 10.0114.405 ± 10.790
Week 120 - Social Function3.297 ± 10.7234.386 ± 11.355
Week 144 - Social Function2.582 ± 10.6383.912 ± 10.929
Week 156 - Social Function2.423 ± 10.6584.351 ± 12.144
Week 12 - Vitality0.570 ± 7.9872.344 ± 8.207
Week 24 - Vitality0.630 ± 8.9962.463 ± 9.461
Week 48 - Vitality2.231 ± 9.2093.029 ± 8.972
Week 72 - Vitality1.082 ± 9.3873.815 ± 8.869
Week 96 - Vitality1.147 ± 9.0523.474 ± 9.071
Week 120 - Vitality1.139 ± 9.4583.224 ± 9.122
Week 144 - Vitality0.386 ± 9.7242.070 ± 9.285
Week 156 - Vitality0.825 ± 9.3422.970 ± 8.831
Week 12 - Mental Component Summary0.986 ± 8.0682.603 ± 8.965
Week 24 - Mental Component Summary1.333 ± 8.9191.936 ± 10.152
Week 48 - Mental Component Summary2.788 ± 9.3012.757 ± 9.141
Week 72 - Mental Component Summary1.434 ± 9.6352.577 ± 9.116
Week 96 - Mental Component Summary1.823 ± 9.4392.415 ± 10.023
Week 120 - Mental Component Summary1.027 ± 10.2862.554 ± 10.548
Week 144 - Mental Component Summary0.580 ± 9.9941.870 ± 9.857
Week 156 - Mental Component Summary0.322 ± 10.0772.269 ± 10.647
Week 12 - Physical Component Summary0.161 ± 6.3411.144 ± 6.078
Week 24 - Physical Component Summary0.878 ± 7.0091.938 ± 6.643
Week 48 - Physical Component Summary1.356 ± 6.8002.797 ± 7.497
Week 72 - Physical Component Summary1.989 ± 6.9413.360 ± 6.985
Week 96 - Physical Component Summary1.497 ± 7.5913.343 ± 6.792
Week 120 - Physical Component Summary2.611 ± 7.2913.175 ± 8.210
Week 144 - Physical Component Summary2.635 ± 7.3743.353 ± 8.042
Week 156 - Physical Component Summary2.133 ± 7.9093.644 ± 8.731
SecondaryPlasma Concentrations of AZD9291

The pharmacokinetics exposure parameters derived from plasma concentrations of AZD9291

Time frame:
Collected at pre-dose, 0.5-1.5hours and 2-4hours post-dose up to 96 weeks (approximately 24 months)
Reported as:
Geometric mean · nM
Plasma Concentrations of AZD9291
nMAZD9291 80mg Tablet
Week 4 - Pre-dose380.2563 ± 60.4465
Week 4 - 0.5-1.5 hours383.9142 ± 74.3191
Week 4 - 2-4 hours463.0098 ± 56.3562
Week 24- Pre-dose288.8266 ± 181.8255
Week 24 - 0.5-1.5 hours303.8269 ± 116.9411
Week 24 - 2-4 hours358.831 ± 116.0567
Week 48- Pre-dose301.7346 ± 125.4901
Week 48 - 0.5-1.5 hours311.3503 ± 101.1574
Week 48 - 2-4 hours375.6666 ± 69.9838
Week 96- Pre-dose287.5375 ± 95.6634
Week 96 - 0.5-1.5 hours273.3198 ± 126.003
Week 96 - 2-4 hours341.5805 ± 79.0578
SecondaryPlasma Concentrations of AZ5104 Metabolites

The pharmacokinetics exposure parameters derived from plasma concentrations of AZ5104 metabolites

Time frame:
From date of dosing to week 96 (approximately 24 months)
Reported as:
Geometric mean · nM
Plasma Concentrations of AZ5104 Metabolites
nMAZ5104
Week 4 - Pre-dose44.4619 ± 66.2108
Week 4 - 0.5-1.5 hours45.2280 ± 67.0500
Week 4 - 2-4 hours49.6081 ± 65.5757
Week 24 - Pre-dose38.7314 ± 111.0996
Week 24 - 0.5-1.5 hours39.1687 ± 86.1118
Week 24 - 2-4 hours41.3251 ± 99.2633
Week 48 - Pre-dose41.1778 ± 53.8923
Week 48 - 0.5-1.5 hours40.9276 ± 53.9916
Week 48 - 2-4 hours42.9143 ± 68.8102
Week 96 - Pre-dose38.0205 ± 81.4442
Week 96 - 0.5-1.5 hours36.9723 ± 101.2317
Week 96 - 2-4 hours39.8057 ± 78.0300
SecondaryPlasma Concentrations of AZ7550 Metabolites

The pharmacokinetics exposure parameters derived from plasma concentrations of AZ7550 metabolites

Time frame:
From date of dosing to week 96 (approximately 24 months)
Reported as:
Geometric mean · nM
Plasma Concentrations of AZ7550 Metabolites
nMAZ7550
Week 4 - Pre-dose44.3492 ± 56.5153
Week 4 - 0.5-1.5 hours44.7386 ± 55.0410
Week 4 - 2-4 hours48.0864 ± 61.8700
Week 24 - Pre-dose40.7113 ± 75.3663
Week 24 - 0.5-1.5 hours40.9375 ± 65.8656
Week 24 - 2-4 hours44.1476 ± 60.2684
Week 48 - Pre-dose41.3862 ± 52.2259
Week 48 - 0.5-1.5 hours41.0467 ± 52.9773
Week 48 - 2-4 hours40.4486 ± 99.6574
Week 96 - Pre-dose28.1890 ± 180.0937
Week 96 - 0.5-1.5 hours30.2419 ± 155.4156
Week 96 - 2-4 hours33.9653 ± 79.2841

Adverse events

Collected over Adverse events with onset date on or after the date of first dose up to and including 28 days following discontinuation of study treatment and before starting subsequent cancer therapy, up to approximately 3 years. All-Cause Mortality assessed up to approximately 7 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD929142/339 (12.4%)68/337 (20.2%)312/337 (92.6%)
Placebo82/343 (23.9%)47/343 (13.7%)262/343 (76.4%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventAZD9291Placebo
PneumoniaInfections and infestations5/3374/343
Acute kidney injuryRenal and urinary disorders2/3370/343
UreterolithiasisRenal and urinary disorders2/3370/343
CataractEye disorders2/3370/343
DiarrhoeaGastrointestinal disorders2/3370/343
Large intestine polypGastrointestinal disorders2/3370/343
InfluenzaInfections and infestations2/3370/343
Femur fractureInjury, poisoning and procedural complications2/3371/343
HyperuricaemiaMetabolism and nutrition disorders2/3371/343
Coronary artery diseaseCardiac disorders1/3371/343
Most frequent other events
Showing 10 of 49
Most frequent other events
EventAZD9291Placebo
DiarrhoeaGastrointestinal disorders158/33771/343
ParonychiaInfections and infestations92/3375/343
Dry skinSkin and subcutaneous tissue disorders84/33723/343
PruritusSkin and subcutaneous tissue disorders70/33730/343
CoughRespiratory, thoracic and mediastinal disorders66/33761/343
StomatitisGastrointestinal disorders59/33715/343
Upper respiratory tract infectionInfections and infestations53/33738/343
NasopharyngitisInfections and infestations50/33736/343
Decreased appetiteMetabolism and nutrition disorders49/33712/343
Dermatitis acneiformSkin and subcutaneous tissue disorders41/33716/343

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD9291PlaceboTotal
Mean62.5 ± 10.361.6 ± 10.562.1 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)AZD9291PlaceboTotal
Female230248478
Male10995204
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9291PlaceboTotal
ASIAN (OTHER THAN CHINESE AND JAPANESE)7765142
CHINESE95100195
HISPANIC OR LATINO12921
JAPANESE4753100
OTHER108116224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9291PlaceboTotal
AMERICAN INDIAN OR ALASKA NATIVE000
ASIAN216218434
BLACK OR AFRICAN AMERICAN000
UNKNOWN OR NOT REPORTED011
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER000
OTHER123
WHITE122122244
Region of Enrollment
Region of Enrollment(Participants)AZD9291PlaceboTotal
Australia7916
Belgium011
Brazil8614
Canada134
China7782159
Germany7512
Spain141630
France459
Hong Kong, S.A.R., China448
Hungary112
Israel9312
Italy151732
Japan465399
Poland4913
Romania224
Russia433982
Sweden112
Thailand161733
Turkey3811
Taiwan, China242246
Ukraine213
United States13821
Viet Nam111324
Korea, Republic Of271845
08

Study locations

238 sites
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Torrance, California 90505, United States
  • Research Site
    Grand Junction, Colorado 81501, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Norwalk, Connecticut 06856, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Pembroke Pines, Florida 33028, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Honolulu, Hawaii 96819, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Elk Grove Village, Illinois 60007, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Brick, New Jersey 08724, United States
  • Research Site
    Florham Park, New Jersey 07932, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    Pawtucket, Rhode Island 02860, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Fort Belvoir, Virginia 22060, United States
  • Research Site
    Bedford Park, 5042, Australia
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Kurralta Park, 5037, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Cachoeira de Itapemirim, 29308-055, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Fortaleza, 60810-180, Brazil
  • Research Site
    Lajeado, 95900000, Brazil
  • Research Site
    Porto Alegre, 90619-900, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    Salvador, 40170-110, Brazil
  • Research Site
    São José do Rio Preto, 15025-100, Brazil
  • Research Site
    São Paulo, 01321-001, Brazil
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100210, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130012, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Dalian, 116027, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200072, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Tianjin, 300051, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xiamen, 361004, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Bron, 69677, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Limoges, 87042, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Paris, 75020, France
  • Research Site
    Aachen, 52074, Germany
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Berlin, 13359, Germany
  • Research Site
    Cologne, 51109, Germany
  • Research Site
    Coswig, 01640, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Gerlingen, 70839, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Hamburg, 20251, Germany
  • Research Site
    Homburg, 66421, Germany
  • Research Site
    Immenhausen, 34376, Germany
  • Research Site
    Kassel, 34125, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    Würzburg, 97074, Germany
  • Research Site
    Hong Kong, 150001, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    King's Park, 150001, Hong Kong
  • Research Site
    Budapest, 1083, Hungary

Showing the first 100 of 238 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Herbst RS, Wu YL, Tsuboi M. Osimertinib in EGFR-Mutated Lung Cancer. Reply. N Engl J Med. 2021 Feb 18;384(7):675-676. doi: 10.1056/NEJMc2033951. No abstract available. PubMed 33596365 ↗
  • Wu YL, Majem M, John T, Grohe C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov K, Wu MF, Akewanlop C, Vu HV, Lee KH, Huang X, Armenteros-Monterroso E, Rukazenkov Y, Herbst RS. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]. J Thorac Oncol. 2026 Sep 13:104179. doi: 10.1016/j.jtho.2026.104179. Online ahead of print. PubMed 42732874 ↗
  • Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18. PubMed 40311309 ↗
  • Herbst RS, John T, Grohe C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Domine M, Ahn MJ, Kowalski DM, Perol M, Sriuranpong V, Ozguroglu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Jun;31(6):1958-1968. doi: 10.1038/s41591-025-03577-y. Epub 2025 Mar 17. PubMed 40097663 ↗
  • Dwyer LJ, Singhal N, Yu B, Kao S. Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report. J Thorac Oncol. 2024 Apr;19(4):650-652. doi: 10.1016/j.jtho.2024.01.001. Epub 2024 Feb 9. PubMed 38340108 ↗
  • Wu D, Li GF. Improving Report of the ADAURA Trial by Distinguishing Treatment-Related Adverse Events From Treatment-Emergent Adverse Events and Assessing Independence of Censoring in Final Disease-Free Survival Analyses. J Clin Oncol. 2023 Sep 10;41(26):4317-4318. doi: 10.1200/JCO.23.00604. Epub 2023 Jun 30. No abstract available. PubMed 37390376 ↗
  • Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohe C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. PubMed 37272535 ↗
  • John T, Grohe C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023 May 24. PubMed 37236398 ↗
  • Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31. PubMed 36720083 ↗
  • John T, Majem M, Legg D, Goldman J. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Target Oncol. 2023 Jan;18(1):1-8. doi: 10.1007/s11523-022-00927-5. Epub 2022 Dec 19. No abstract available. PubMed 36534268 ↗
  • Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clin Cancer Res. 2022 Jun 1;28(11):2286-2296. doi: 10.1158/1078-0432.CCR-21-3530. PubMed 35012927 ↗
  • Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang Z, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Atasoy A, Herbst RS, Tsuboi M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol. 2022 Mar;17(3):423-433. doi: 10.1016/j.jtho.2021.10.014. Epub 2021 Nov 2. PubMed 34740861 ↗
  • Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncol. 2021 Dec 1;17(35):4827-4835. doi: 10.2217/fon-2021-0752. Epub 2021 Nov 1. PubMed 34723634 ↗
  • Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. PubMed 32955177 ↗
  • Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1. PubMed 29789220 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Apr 2022, 77 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 77 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2015
First posted
Jul 29, 2015
StartActual
Oct 21, 2015
Primary completionActual
Apr 11, 2022
CompletionEst.
Jan 31, 2029
Results first posted
Jul 27, 2021
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02511106
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 29, 2015
Start date
Oct 21, 2015
Primary completion
Apr 11, 2022
Completion
Jan 31, 2029 (estimated)
Results posted
Jul 27, 2021
Last update
Sep 11, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion